Key points are not available for this paper at this time.
Outcome after AZA failure is poor. Our results should serve as a basis for designing second-line clinical trials in this population.
Prébet et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: